Organon & Co.

NYSE:OGN

Drug Manufacturers - General

Healthcare
$13.92 +0.04%

+$0.01 today

Market cap
$3.66B
Beta
1.54
P/E (TTM)
14.2
EPS (TTM)
$0.94
Dividend yield
0.60%
52W Low $5.69High $13.49

Volume 3.90M

Average 8.57M

OGN Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

Organon & Co.NYSE: OGN

Stock-Based Compensation · Q3 FY2026 · quarter ended Sep 2026

Stock-based compensation declines year over year

Q3 FY2026 stock-based compensation of $21M fell 12.5% year over year, ahead of the -70.8% change in trailing-twelve-month stock-based compensation. Over 3 fiscal years it compounded at +0.9% a year.

Context

  • Stock-based compensation amounted to 1.2% of revenue in FY2025, down 0.4 pp from a year earlier.
  • Stock-based compensation increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth of -12.5% holds above the trailing-twelve-month pace of -70.8%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterSep 2026
$21M+210.8% QoQ
Last fiscal yearDec 2025
$77M-26.7% YoY
LTMSep 2026
$28.04M-70.8% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-12.5%——
1 year-26.7%——
3-year CAGR+0.9%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
77M USD
Year-over-year change
-26.7%
4-year CAGR
+6.9%

Stock-Based Compensation vs competitors

How OGN compares with its peers on the latest reported figures

  • OGN's LTM Sep 2026 stock-based compensation of $28.04M is the 3rd largest of the 10 companies compared; the peer median is $12.18M.
  • Its year-over-year change of -70.8% is the 6th highest of 9, against a peer median of -34.5%.
  • Stock-based compensation amounts to 0.5% of revenue for OGN, versus a peer median of 2.5%.
OGN Competitors Peer median
Stock-Based Compensation for OGN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
HRMYHarmony Biosciences Holdings, Inc.LTM Jun 2026$40.95M -9.9%+18.6%4.3%
TLRYTilray Brands, Inc.LTM Feb 2026$37.82M ——3.2%
OGNOrganon & Co.LTM Sep 2026$28.04M -70.8%+0.9%0.5%
MDPediatrix Medical Group, Inc.LTM Sep 2026$21.28M +37.8%+3.8%1.1%
NUVBNuvation Bio Inc.LTM Jun 2026$19.89M -153.0%+30.1%11.7%
ALVOAlvotechLTM Mar 2026$16.07M +356.7%+19.0%2.9%
SEMSelect Medical Holdings CorporationLTM Mar 2026$12.18M -86.9%-23.8%0.2%
GRDNGuardian Pharmacy Services, Inc.LTM Jun 2026$10.23M -92.4%—0.7%
AUPHAurinia Pharmaceuticals Inc.LTM Jun 2026$7.89M -59.1%-23.1%2.5%
PAHCPhibro Animal Health CorporationLTM Mar 2026$952K +32.8%—0.1%
Peer median (excluding OGN) $12.18M-34.5%+11.2%2.5%

Competitors are the stored peer set for OGN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income1.35B917M1.02B864M187M
Depreciation & Amortization195M212M236M277M361M
Deferred Income Tax(288M)(18M)(485M)(160M)63M
Stock-Based Compensation59M75M101M105M77M
Change in Working Capital702M(452M)(155M)(278M)(247M)
Accounts Receivables(277M)(123M)(212M)383M79M
Inventory(138M)(220M)(230M)(131M)(13M)
Accounts Payables663M(237M)163M(157M)(217M)
Other Working Capital454M128M124M(373M)(96M)
Other Non-Cash Items439M124M79M131M259M
Operating Cash Flow2.46B858M799M939M700M
Capital Expenditures(488M)(427M)(261M)(351M)(162M)
Acquisitions (Net)(185M)(124M)(2M)(166M)(198M)
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities192M131M1M4M0
Investing Cash Flow(481M)(420M)(260M)(513M)(390M)
Debt Repayment7.85B(108M)(258M)(11M)(458M)
Common Stock Issued00000
Common Stock Repurchased00(17M)(22M)0
Dividends Paid(145M)(290M)(294M)(297M)(88M)
Other Financing Activities(9.03B)(35M)0(38M)(15M)
Financing Cash Flow(1.33B)(433M)(569M)(368M)(561M)
Effect of Forex Changes23M(36M)17M(76M)150M
Net Change in Cash667M(31M)(13M)(18M)(101M)
Free Cash Flow1.97B431M538M588M538M

Organon & Co.

NYSE:OGN

Intrinsic Alpha fair value

Locked

Current Price

$13.92

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.